PT613371E - Nova combinacao de formoterol e budesonido - Google Patents

Nova combinacao de formoterol e budesonido

Info

Publication number
PT613371E
PT613371E PT92924683T PT92924683T PT613371E PT 613371 E PT613371 E PT 613371E PT 92924683 T PT92924683 T PT 92924683T PT 92924683 T PT92924683 T PT 92924683T PT 613371 E PT613371 E PT 613371E
Authority
PT
Portugal
Prior art keywords
formoterol
budesonide
separately
budsonido
new combination
Prior art date
Application number
PT92924683T
Other languages
English (en)
Portuguese (pt)
Inventor
Christer Carl Gustav Carling
Jan William Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8208509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT613371(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT613371E publication Critical patent/PT613371E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Control Of Positive-Displacement Air Blowers (AREA)
  • Fats And Perfumes (AREA)
  • Edible Oils And Fats (AREA)
PT92924683T 1991-12-18 1992-12-07 Nova combinacao de formoterol e budesonido PT613371E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91311761 1991-12-18

Publications (1)

Publication Number Publication Date
PT613371E true PT613371E (pt) 2002-07-31

Family

ID=8208509

Family Applications (1)

Application Number Title Priority Date Filing Date
PT92924683T PT613371E (pt) 1991-12-18 1992-12-07 Nova combinacao de formoterol e budesonido

Country Status (20)

Country Link
US (2) US5674860A (show.php)
JP (1) JP3342484B2 (show.php)
AT (1) ATE213946T1 (show.php)
AU (1) AU673660C (show.php)
CA (2) CA2123909C (show.php)
CZ (2) CZ288032B6 (show.php)
DE (2) DE10299033I2 (show.php)
DK (1) DK0613371T3 (show.php)
ES (1) ES2172510T3 (show.php)
HR (1) HRP921445B1 (show.php)
HU (2) HU0004452D0 (show.php)
IS (1) IS3959A (show.php)
NO (2) NO306452B1 (show.php)
NZ (1) NZ246050A (show.php)
PT (1) PT613371E (show.php)
SG (1) SG48301A1 (show.php)
SI (1) SI9200403B (show.php)
SK (2) SK285910B6 (show.php)
WO (1) WO1993011773A1 (show.php)
YU (1) YU49083B (show.php)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
SE9700134D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5863910A (en) * 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
ATE415149T1 (de) * 1997-03-20 2008-12-15 Schering Corp Dosierungsform eines pulveragglomerates
SE9701956D0 (sv) * 1997-05-23 1997-05-23 Astra Ab New composition of matter
EP1009408A1 (en) * 1997-06-27 2000-06-21 Astra Aktiebolag New combination of antiasthma medicaments
AU766637B2 (en) * 1997-09-19 2003-10-23 Astrazeneca Ab New use for budesonide and formoterol
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
WO1999039699A1 (en) * 1998-02-09 1999-08-12 Rtp Pharma, Inc. Treatment of chronic inflammatory disorders of the gastrointestinal tract
AU762246B2 (en) * 1998-02-11 2003-06-19 Rtp Pharma Corporation Method and composition for treatment of inflammatory conditions
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6234167B1 (en) 1998-10-14 2001-05-22 Chrysalis Technologies, Incorporated Aerosol generator and methods of making and using an aerosol generator
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
UA73726C2 (show.php) * 1998-10-30 2005-09-15 Baker Norton Pharma
US6235725B1 (en) * 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
PT1131059E (pt) 1998-11-13 2003-07-31 Jago Res Ag Po seco para inalacao
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
BR0013935A (pt) * 1999-09-13 2002-05-14 Bridge Pharma Inc IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
CO5251465A1 (es) * 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
PL358375A1 (en) * 2000-04-13 2004-08-09 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
US6883516B2 (en) 2000-04-27 2005-04-26 Chrysalis Technologies Incorporated Method for generating an aerosol with a predetermined and/or substantially monodispersed particle size distribution
MY136453A (en) 2000-04-27 2008-10-31 Philip Morris Usa Inc "improved method and apparatus for generating an aerosol"
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
US7077130B2 (en) 2000-12-22 2006-07-18 Chrysalis Technologies Incorporated Disposable inhaler system
US6681998B2 (en) 2000-12-22 2004-01-27 Chrysalis Technologies Incorporated Aerosol generator having inductive heater and method of use thereof
US6501052B2 (en) 2000-12-22 2002-12-31 Chrysalis Technologies Incorporated Aerosol generator having multiple heating zones and methods of use thereof
US6491233B2 (en) 2000-12-22 2002-12-10 Chrysalis Technologies Incorporated Vapor driven aerosol generator and method of use thereof
US6799572B2 (en) 2000-12-22 2004-10-05 Chrysalis Technologies Incorporated Disposable aerosol generator system and methods for administering the aerosol
US6701921B2 (en) 2000-12-22 2004-03-09 Chrysalis Technologies Incorporated Aerosol generator having heater in multilayered composite and method of use thereof
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20050070487A1 (en) * 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US6568390B2 (en) 2001-09-21 2003-05-27 Chrysalis Technologies Incorporated Dual capillary fluid vaporizing device
US6640050B2 (en) 2001-09-21 2003-10-28 Chrysalis Technologies Incorporated Fluid vaporizing device having controlled temperature profile heater/capillary tube
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
AU2002342241B2 (en) 2001-11-01 2007-07-19 Novartis Ag Spray drying methods and compositions thereof
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US6681769B2 (en) 2001-12-06 2004-01-27 Crysalis Technologies Incorporated Aerosol generator having a multiple path heater arrangement and method of use thereof
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US6804458B2 (en) 2001-12-06 2004-10-12 Chrysalis Technologies Incorporated Aerosol generator having heater arranged to vaporize fluid in fluid passage between bonded layers of laminate
US6701922B2 (en) 2001-12-20 2004-03-09 Chrysalis Technologies Incorporated Mouthpiece entrainment airflow control for aerosol generators
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
SE0203376D0 (sv) * 2002-11-15 2002-11-15 Astrazeneca Ab New process
WO2004052374A1 (en) 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
US7311790B2 (en) * 2003-04-25 2007-12-25 Siemens Power Generation, Inc. Hybrid structure using ceramic tiles and method of manufacture
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AU2003254429A1 (en) 2003-08-06 2005-02-25 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
US7367334B2 (en) 2003-08-27 2008-05-06 Philip Morris Usa Inc. Fluid vaporizing device having controlled temperature profile heater/capillary tube
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
ATE481996T1 (de) 2004-07-16 2010-10-15 Almirall Sa Inhalator für die abgabe von pharmzeutischen pulver, und ein pulverkassette zur verwendung mit diesem inhalator
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
ATE552032T1 (de) 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20070293460A1 (en) * 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
US20100119609A1 (en) * 2006-10-17 2010-05-13 John Daniel Dobak Methods, compositions, and formulations for the treatment of thyroid eye disease
DK2063940T3 (da) 2006-12-22 2012-05-07 Almirall Sa Inhalationsapparat til lægemidler i pulverform
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
EP2327403A3 (en) 2007-02-19 2011-08-31 Cipla Limited Pharmaceutical combinations of at least two bronchodilators
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
WO2009026434A1 (en) * 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
BRPI1011220B1 (pt) 2009-05-29 2020-03-10 Pearl Therapeutics, Inc. Composição farmacêutica administrável a partir de um inalador de dose medida compreendendo um meio de suspensão compreendendo um propelente, duas ou mais espécies diferentes de partículas de agente ativo e uma ou mais espécies de partículas respiráveis em suspensão
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SG182485A1 (en) * 2010-01-15 2012-08-30 Lithera Inc Lyophilized cake formulations
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
CN105832681A (zh) 2010-11-24 2016-08-10 纽赛蒂克斯公司 选择性、亲脂性及长效型β激动剂单一治疗调配物和用于肥胖及外形凸起的美容治疗的方法
WO2012154725A2 (en) * 2011-05-09 2012-11-15 University Of Houston Steroid-sparing effects of beta-adrenergic inverse agonists and use thereof
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
TR201902687T4 (tr) 2013-03-15 2019-03-21 Pearl Therapeutics Inc İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
MX375783B (es) * 2015-12-04 2025-03-07 Mexichem Fluor Sa De Cv Composiciones farmacéuticas que comprenden un compuesto de formoterol, un corticosteroide y un componente propelente.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (show.php) * 1972-05-19 1975-08-18 Bofors Ab
FR2651678B1 (fr) * 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate

Also Published As

Publication number Publication date
DK0613371T3 (da) 2002-05-13
HK1010339A1 (en) 1999-06-17
NZ246050A (en) 1995-12-21
CZ288032B6 (cs) 2001-04-11
SI9200403B (en) 2001-12-31
HRP921445A2 (en) 1994-12-31
IS3959A (is) 1993-06-19
AU3085892A (en) 1993-07-19
AU673660C (en) 2002-07-25
SK285910B6 (sk) 2007-10-04
CA2123909C (en) 2002-10-01
CZ143494A3 (en) 1994-12-15
CZ291455B6 (cs) 2003-03-12
SG48301A1 (en) 1998-04-17
NO2001014I2 (no) 2007-06-11
ATE213946T1 (de) 2002-03-15
DE10299033I1 (de) 2003-01-23
DE69232462D1 (de) 2002-04-11
HU227519B1 (en) 2011-07-28
NO942116L (show.php) 1994-06-07
US5674860A (en) 1997-10-07
HUT75156A (en) 1997-04-28
CA2356145A1 (en) 1993-06-24
DE10299033I2 (de) 2005-07-07
JPH07502036A (ja) 1995-03-02
JP3342484B2 (ja) 2002-11-11
YU49083B (sh) 2003-10-31
WO1993011773A1 (en) 1993-06-24
NO306452B1 (no) 1999-11-08
HU0004452D0 (show.php) 2001-01-29
ES2172510T3 (es) 2002-10-01
SK73394A3 (en) 1995-03-08
NO942116D0 (no) 1994-06-07
DE69232462T2 (de) 2002-10-10
HRP921445B1 (en) 2011-08-31
SK282826B6 (sk) 2002-12-03
YU106192A (sh) 1996-01-08
US5972919A (en) 1999-10-26
HU9401843D0 (en) 1994-09-28
AU673660B2 (en) 1996-11-21
SI9200403A (en) 1993-06-30
CA2123909A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
PT613371E (pt) Nova combinacao de formoterol e budesonido
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
NO923859L (no) Medikament
GB2235626B (en) Inhalation medicaments for treating respiratory disorders
EE04330B1 (et) Levosimendani transmukoossed koostised ja nende kasutamine ravimi valmistamiseks
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
DK0533896T3 (show.php)
MD1716B2 (en) Use of melatonin for treatment of patients dependent on benzodiazepine
Brewer III et al. Streptomycin in tuberculous tracheobronchitis
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
RU93032284A (ru) Способ лечения заболевания легких
AR002946A1 (es) Un conjunto para uso en el tratamiento o la prevencion de la osteoporosis en los mamiferos de acuerdo con una dieta ciclica.
RU93002840A (ru) Способ лечения хронического гнойного эндобронхита
Macarthur Effect of Nikethamide by Mouth in Man
Garmash et al. Experience in the combined treatment of different clinical forms of chronic bronchitis with new phytotherapeutic mixtures
UA29778A (uk) Спосіб лікування легеневої та легенево-серцевої недостатності
MD1609G2 (ro) Metodă de tratament al stomatitei aftoase recidivante cronice
Simon The International Medical Corps
ITMI930625U1 (it) Struttura di inalatore per uso medicale particolarmente per bambini
TH35334A (th) การรักษาโรคหืด
UA42534A (uk) Спосіб лікування пневмоцистозу у хворих на хронічні неспецифічні захворювання легень
KR910005856A (ko) 호흡기 질환 치료용 제약 조성물
UA7190A (uk) Спосіб лікування запально-гнійних захворювань легень